Biologic protease inhibitors as novel therapeutic agents

Biologic protease inhibitors as novel therapeutic agents,10.1016/j.biochi.2010.03.010,Biochimie,Christopher J. Scott,Clifford C. Taggart

Biologic protease inhibitors as novel therapeutic agents   (Citations: 5)
BibTex | RIS | RefWorks Download
Deregulated proteolytic activities frequently have causative or exacerbative functions in pathological conditions such as cancer and inflammatory disease. Many proteases therefore represent therapeutic targets, but the generation of successful small molecule drugs is often limited by the ability to achieve sufficient specificity of action. Consequently, several proteases have been deemed as unsuitable drug targets due to the inability to target them successfully. In an effort to circumvent these issues, much interest has recently focused on the development and application of biologic inhibitors. In this review, the latest research in the development of biologic protease inhibitors is examined. This includes a review of engineered kunitz and other inhibitory domains as well as the application of antibodies as therapeutically viable inhibitors.
Journal: Biochimie , vol. 92, no. 11, pp. 1681-1688, 2010
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...At least partially that can be explained by inability to produce small molecule inhibitors with the desired selectivity and bioavailability [77]...
    • ...Recent interest in development of biologic inhibitors such as antibodies may stimulate the progress in the therapeutic targeting of protease species [77], although caution is warranted because anti-apoptotic drugs might potentially promote the excessive cell growth seen in malignancies...

    Melissa Heightmanet al. Proteases and Fibrosis

Sort by: